Abstract
Background
Lymphatic mapping and sentinel lymph node (SLN) biopsy have the potential to become the standard of care for nodal staging in breast cancer patients, but their widespread utility outside of university-based centers has not been determined. This study describes the final results from a national multi-institutional trial designed to determine the role of preoperative lymphoscintigraphy in breast lymphatic mapping, the rate of success for finding an SLN, and the rate of skip metastasis for patients with invasive breast cancer across all practice scenarios.
Methods
Lymphatic mapping techniques involving the combined use of blue dye and radiocolloid were taught to participating surgeons through a formal 2-day training course at the Moffitt Cancer Center. In protocol 1, surgeons performed their first 20 to 25 cases of breast mapping with SLN biopsy followed by complete axillary lymph node dissection. In protocol 2, after the learning phase, surgeons did not perform axillary lymph node dissection unless a SLN was positive for metastatic disease.
Results
Forty-two institutions, including 12 university-based research centers participated in the trial. From July 1, 1997, through January 31, 1999, a total of 965 patients were accrued. Lymphoscintigraphy identified drainage to an axillary SLn 64% of the time, but by using sensitive handheld gamma probes at the time of the operation, an axillary SLN could be identified 86% of the time. The rate of success for finding an axillary SLN was 92.8% for cases performed at the Moffitt Cancer Center. For other university centers, the rate of success of identifying an axillary SLn was 91.4%, and for other community/regional hospitals in the study, it was 85.2%. For cases in which protocol 1 was followed, the rate of false-negative SLN biopsy was 4%. There was no axillary nodal recurrence after a negative SLN in protocol 2 when a negative SLN biopsy was followed by observation. The median follow-up for the patients on protocol 2 was 16 months.
Conclusions
These data show a high rate of success for finding an axillary SLN and a low rate of skip metastasis in a national multicenter study of lymphatic mapping for breast cancer. This study suggest that SLN biopsy for breast cancer can be performed successfully in community/regional hospitals, as well as in major university-based centers.
Similar content being viewed by others
References
Hill AD, Tran KN, Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer.Ann Surg 1999;229: 528–35.
Beitsch PD, Clifford E, Whitworth P, Abarca A. Improved lymphatic mapping technique for breast cancer.Breast J 2001;7:219–23.
Haddad FF, Costello D, Reintgen DS. Radioguided surgery for melanoma.Surg Oncol Clin North Am 1999;8:413–26.
Uren RF, Howman-Giles RB, Thompson JF. Mammary lymphoscintigraphy in breast cancer.J. Nucl Med 1995;36:1775–80.
Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer.N Engl J Med 1998;339:941–6.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Shivers, S., Cox, C., Leight, G. et al. Final results of the department of defense multicenter breast lymphatic mapping trial. Annals of Surgical Oncology 9, 248–255 (2002). https://doi.org/10.1007/BF02573062
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02573062